The
global Minimal
Residual Disease Testing Market size is expected to reach USD 4.50
billion by 2030, at a CAGR of 11.45% from 2023 to 2030, according to a new
report by Grand View Research, Inc. The adoption of MRD testing as a novel
diagnostic and prognostic assay facilitates robust moderation of treatment
regimes to treat all kinds of hematological malignancies. Measurement of
therapeutic outcomes is critical for the successful adoption of a given cancer
therapeutic regime.
MRD
generates important molecular information to better understand the cancer conditions
and ultimately work towards leveraging treatment outcomes. Therefore, MRD
testing is increasingly used as an end-point analysis step in numerous clinical
trial studies for oncology-based research and also effectively records the
variations in outcomes due to individual genetic characteristics. For instance,
in November 2020, Adaptive Biotechnologies Corporation, entered into a
collaboration with GlaxoSmithKline plc., to use its clonoSEQ assay for the
assessment of residual cancer cells after treatment with GSK’s hematology
therapeutics.
Surgical
removal of tumors with other associative therapies does not essentially mean,
that the cancerous cells are removed completely. Traces of cancer can remain in
the body parts and bloodstream. The diagnosis of such residual cells is crucial
for deciding upon the need for further rounds of chemotherapy and radiation.
Researchers are devising non-invasive tests to effectively detect MRD. For
instance, in February 2022, a blood test from C2i Genomics quantified the
residual cancer cells after surgical oncology procedures. The C2inform test
also achieved the CE mark clearance and is offered as a
‘software-as-a-medical-device’ MRD test in Europe.
Cancer
therapeutics are effectively moderated to avoid a residue of tumorous
cells using the relevant clinical evidence and are also personalized based on
specific progression profiles in an individual. Numerous research studies are
driving the need for consideration of individual genetic characteristics for
effective treatment. For instance, in October 2022, Adaptive Biotechnologies
Corporation partnered with Epic for increasing access to MRD monitoring in
blood cancers. Moreover, in February 2021, Natera Inc., collaborated with
Personalis Inc., to understand the outcomes of personalized cancer care by
integrating the NeXT tumor profiling (by Personalis) and the personalized ctDNA
platform Signatera’s diagnostic products (by Natera, Inc.,) for effectively designing
the treatment monitoring regime and assessment of MRD.
List of Key Players in the Minimal Residual Disease
Testing Market
- Exact Sciences Corporation
- GRAIL, LLC
- Veracyte, Inc.
- Natera, Inc.
- Guardant Health
- F. Hoffmann-La Roche Ltd
- FOUNDATION MEDICINE, INC.
- QIAGEN
- mdxhealth
- Bio-Techne
Related Press
Release Minimal
Residual Disease Testing Market Report
Minimal Residue Disease Testing Market Report Highlights
- The flow
cytometry segment held a dominant share in the minimal residual
disease testing market in 2022 owing to the high sensitivity and wide
applicability of MRD testing
- The
hematological malignancy segment is projected to grow at the fastest rate
over the forecast period owing to the increasing prevalence of
hematological malignancy
- The
hospitals and specialty clinics segment is the highest revenue-generating
segment in 2022 owing to the availability of advanced diagnostic devices
and skilled professionals in hospitals and specialty clinics
- North
America dominated the minimal residual disease testing market in 2022,
which is attributed to the growing prevalence of hematological
malignancies in the region aided by a well-developed reimbursement
landscape
Minimal Residual Disease Testing Market
Report Scope
|
Report Attribute |
Details |
|
Market size value in 2023 |
USD 2,199.96 million |
|
Revenue forecast in 2030 |
USD 4.50 billion |
|
Growth rate |
CAGR of 11.45% from 2023 to 2030 |
|
Base year for estimation |
2022 |
|
Historical data |
2018 - 2021 |
|
Forecast period |
2023 - 2030 |
Related Reports@
Respiratory Disease Testing Market
Point of Care Infectious Disease Testing
Market
Minimal Residue Disease Testing Market Segmentation
Grand
View Research has segmented the global minimal residual disease testing market
report based on technology, cancer type, end-use, and region:
Minimal Residual Testing Technology Outlook (Revenue, USD
Million, 2018 - 2030)
- Flow
Cytometry
- Polymerase
Chain Reaction (PCR)
- Next
Generation Sequencing (NGS)
- Others
Minimal Residual Testing Cancer Type Outlook (Revenue,
USD Million, 2018 - 2030)
- Hematological
Malignancy
- Leukemia
- Lymphoma
- Solid Tumors
Minimal Residual Testing End-Use Outlook (Revenue, USD
Million, 2018 - 2030)
- Hospitals
and Speciality Clinics
- Diagnostic
Laboratories
- Academic and
Research Institutes
- Others
Minimal Residual Testing Regional Outlook (Revenue, USD
Million, 2018 - 2030)
- North
America
- U.S.
- Canada
- Europe
- UK
- Germany
- France
- Spain
- Italy
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- Thailand
- South Korea
- Latin
America
- Brazil
- Mexico
- Argentina
- Middle East
& Africa
- South
Africa
- Saudi
Arabia
- UAE
- Kuwait
About Us:
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, the
company offers market intelligence studies ensuring relevant and fact-based
research across a range of industries including technology, chemicals,
materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
